UROHTLV: Urological Physical Therapy in HTLV-1 With Urinary Symptoms

Sponsor
Hospital Universitário Professor Edgard Santos (Other)
Overall Status
Completed
CT.gov ID
NCT01651819
Collaborator
(none)
20
1
1
40.9
0.5

Study Details

Study Description

Brief Summary

Urological physical therapy is described to improve urinary symptoms in patients with myelopathy or neurological dysfunction and to increase the quality of life. Although it was never tested on HTLV-1 associated overactive bladder syndrome, an disabling disease that is common seen in HAM/TSP patients but can also appear as an isolated form. Our hypothesis is that urological physical therapy can improve urinary symptoms like incontinence, urgency and nocturia in HTLV-1 infected population with those complains.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Urological physical therapy
N/A

Detailed Description

The T-lymphotropic virus type 1 (HTLV-1) is an human retrovirus that was proved to be the main agent of the acute T cell lymphoma/leukemia (ATLL) and a progressive neurological disease called HTLV-1 associated myelopathy/ tropical spastic paraparesis (HAM/TSP).

The HTLV-1 was first isolated in 1980 and it is endemic in Japan, Caribbean, Africa and South America. It is estimated that about 20 million people is infected worldwide. In Brazil it is present in all states with variable prevalences. The factors associated with HTLV-1 transmission in Brazil are related to the social and demographic condition, characterized by rural exodus and increase of urban population in the coast areas.

Several studies based in Brazil reported that the epicenter of HTLV-1 infection is on Bahia, Maranhão and Pernambuco with the highest prevalence of 1,8% in Salvador, Bahia capital.

The urinary incontinence is a bladder-sphincter disturbance often found in HTLV-1 patients. In this infection the most common pathology finding is overactive bladder syndrome due detrusor overactivity and sphincter-detrusor dyssynergia and the symptoms are urgency, nocturia and incontinence.

This disabling disease is associated with psychosocial issues like loss of self confidence, social isolation and reduced quality of life.

The physical therapy treatment have the objective of promote social adequacy and reestablish the bladder function. It is based on resources like: bladder reeducation, biofeedback, kinesiotherapy of the pelvic wall, utilization of vaginal cones and electrostimulation.

Those can be associated or not with anticholinergic drugs and bladder catheterization.

The need of urologic and gynecologic physical therapy follow up in patients with HTLV-1 and neurogenic bladder is important to reduce disability, preserve pelvic muscles and renal function.

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Effects of Physiotherapy in the Treatment of Neurogenic Bladder in Patients Infected With Human T-Lymphotropic Virus 1
Actual Study Start Date :
Mar 1, 2012
Actual Primary Completion Date :
Dec 30, 2014
Actual Study Completion Date :
Jul 30, 2015

Arms and Interventions

Arm Intervention/Treatment
Experimental: Urological physical therapy

Urologic physical therapy is going to be apply in 20 patients with HTLV-1 infection and overactive bladder symptoms like urgency, incontinence and nocturia. There will be 20 sessions with one hour duration and a interval of 3 or 4 days between the sections.

Procedure: Urological physical therapy
Individual patient attending with one hour duration beginning with Behavior therapy and education, teaching urinary maneuvers, water adequate intake. Second part is manual therapy an Kinesiotherapy with specific exercises, followed by patient repetition. Last part is constituted by electrotherapy for specific muscle stimulation and biofeedback.
Other Names:
  • Electrotherapy;
  • Behavior therapy;
  • Manual therapy;
  • Kinesiotherapy.
  • Outcome Measures

    Primary Outcome Measures

    1. Reduction in urinary symptoms [6 months]

      reduce or cure the complaints of urinary symptoms measured by daily and nocturnal frequency, presence of incontinence, urgency, dysuria.

    Secondary Outcome Measures

    1. Improve in quality of life [6 months]

      improving the quality of life measured by King' Health scale that is applied before and after therapy

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients with HTLV-1 with more than 18 years and neurogenic bladder defined by urodynamic study.
    Exclusion Criteria:
    • Diabetes Mellitus,

    • Stroke,

    • Multiple Sclerosis,

    • Parkinson disease,

    • use of pacemaker,

    • urinary infection.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Hospital Universitário Prof. Edgard Santos Salvador Bahia Brazil

    Sponsors and Collaborators

    • Hospital Universitário Professor Edgard Santos

    Investigators

    • Principal Investigator: Rosana Andrade, Master, Federal University of Bahia

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    ROSANA CRISTINA PEREIRA DE ANDRADE, coordenadora do Ambulatório de Fisioterapia Nas Disfunções perineias, Hospital Universitário Professor Edgard Santos
    ClinicalTrials.gov Identifier:
    NCT01651819
    Other Study ID Numbers:
    • ROAND2012
    First Posted:
    Jul 27, 2012
    Last Update Posted:
    Oct 5, 2018
    Last Verified:
    Oct 1, 2018
    Keywords provided by ROSANA CRISTINA PEREIRA DE ANDRADE, coordenadora do Ambulatório de Fisioterapia Nas Disfunções perineias, Hospital Universitário Professor Edgard Santos
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 5, 2018